Tiger Brokers

Japan's AMED Extends 1.5 Billion Yen Grant to J-Pharma's Biliary Tract Cancer Treatment Trial; Shares Rise 4%

MT Newswires Live
Oct 05

The Japan Agency for Medical Research and Development (AMED) has chosen J-Pharma's (TYO:520A) Beacon-BTC trial for a grant support of up to 1.5 billion yen, according to a Monday filing with the Tokyo Stock Exchange.

The pharmaceutical company's global phase three clinical trial assesses the LAT1 inhibitor nanvuranlat (JPH203) as a second-line biliary tract cancer treatment.

The company expects the grant to aid in completing part A of the trial, which looks to achieve the optimal dosing regiment and is underway in the U.S.

The company plans to grow part A into a multinational clinical trial that includes Japan.

The grant does not cover funding for a feasibility study.

The trial's research and development period will run from October to December 2028.

Shares of the company rose more than 4% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10